Citations (12)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Giovanni Luca Ceresoli & Antonio Rossi. (2019) Approved and emerging treatments of malignant pleural mesothelioma in elderly patients. Expert Review of Respiratory Medicine 13:12, pages 1179-1188.
Read now
Read now
Muhammad Omer Jamil, Mary S Jerome, Deborah Miley, Katri S Selander & Francisco Robert. (2017) A pilot study of zoledronic acid in the treatment of patients with advanced malignant pleural mesothelioma. Lung Cancer: Targets and Therapy 8, pages 39-44.
Read now
Read now
Giulia Pinton, Arcangela Gabriella Manente, Daniela Tavian, Laura Moro & Luciano Mutti. (2013) Therapies currently in Phase II trials for malignant pleural mesothelioma. Expert Opinion on Investigational Drugs 22:10, pages 1255-1263.
Read now
Read now
Articles from other publishers (9)
Viktoria Laszlo, Zsuzsanna Valko, Ildiko Kovacs, Judit Ozsvar, Mir Alireza Hoda, Thomas Klikovits, Dora Lakatos, Andras Czirok, Tamas Garay, Alexander Stiglbauer, Thomas H. Helbich, Marion Gröger, Jozsef Tovari, Walter Klepetko, Christine Pirker, Michael Grusch, Walter Berger, Frank Hilberg, Balazs Hegedus & Balazs Dome. (2018)
Nintedanib Is Active in Malignant Pleural Mesothelioma Cell Models and Inhibits Angiogenesis and Tumor Growth
In Vivo
. Clinical Cancer Research 24:15, pages 3729-3740.
Crossref
Crossref
Luana Calabrò, Giovanni Luca Ceresoli, Armida D’Incecco, Arnaud Scherpereel, Joachim Aerts & Michele Maio. (2017) Immune checkpoint therapy of mesothelioma: Pre-clinical bases and clinical evidences. Cytokine & Growth Factor Reviews 36, pages 25-31.
Crossref
Crossref
Akiko Harada, Junji Uchino, Taishi Harada, Noriaki Nakagaki, Junko Hisasue, Masaki Fujita & Koichi Takayama. (2017) Vascular endothelial growth factor promoter-based conditionally replicative adenoviruses effectively suppress growth of malignant pleural mesothelioma. Cancer Science 108:1, pages 116-123.
Crossref
Crossref
Luana Calabrò, Giovanni Luca Ceresoli, Alessandra di Pietro, Ornella Cutaia, Aldo Morra, Ramy Ibrahim & Michele Maio. (2014) CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy?. Cancer Immunology, Immunotherapy 64:1, pages 105-112.
Crossref
Crossref
Shang Li, Yuan Ye Dang, Ginny Oi Lam Che, Yiu Wa Kwan, Shun Wan Chan, George Pak Heng Leung, Simon Ming Yuen Lee & Maggie Pui Man Hoi. (2014) VEGFR tyrosine kinase inhibitor II (VRI) induced vascular insufficiency in zebrafish as a model for studying vascular toxicity and vascular preservation. Toxicology and Applied Pharmacology 280:3, pages 408-420.
Crossref
Crossref
Giovanni Luca Ceresoli. (2014) Second-line treatment in malignant pleural mesothelioma: translating the evidence into clinical practice. Lung Cancer Management 3:3, pages 263-271.
Crossref
Crossref
Laura Giusti, Ylenia Da Valle, Alessandra Bonotti, Elena Donadio, Federica Ciregia, Tiziana Ventroni, Rudy Foddis, Gino Giannaccini, Giovanni Guglielmi, Alfonso Cristaudo & Antonio Lucacchini. (2014) Comparative proteomic analysis of malignant pleural mesothelioma evidences an altered expression of nuclear lamin and filament-related proteins. PROTEOMICS - Clinical Applications 8:3-4, pages 258-268.
Crossref
Crossref
G L Ceresoli, P A Zucali, M Mencoboni, M Botta, F Grossi, D Cortinovis, N Zilembo, C Ripa, M Tiseo, A G Favaretto, H Soto-Parra, F De Vincenzo, A Bruzzone, E Lorenzi, L Gianoncelli, B Ercoli, L Giordano & A Santoro. (2013) Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma. British Journal of Cancer 109:3, pages 552-558.
Crossref
Crossref
Brooke T. Mossman, Arti Shukla, Nicholas H. Heintz, Claire F. Verschraegen, Anish Thomas & Raffit Hassan. (2013) New Insights into Understanding the Mechanisms, Pathogenesis, and Management of Malignant Mesotheliomas. The American Journal of Pathology 182:4, pages 1065-1077.
Crossref
Crossref